I would like you to help me preparing a presentation at journal club meeting/critical appraisal. I'm a Haematology registrar and I will be presenting in front of our Haematologys team composed of consultants, registrars, SHOs, interns and advance nurse practitioners. I would like to present this trial : Talquetamab–Daratumumab in Relapsed or Refractory Myeloma. this is a link to the trial https://www.nejm.org/doi/pdf/10.1056/NEJMoa2604657
I would like you to help me preparing a presentation at journal club meeting/critical appraisal. I'm a Haematology registrar and I will be presenting in front of our Haematologys team composed of consultants, registrars, SHOs, interns and advance nurse practitioners. I would like to present this trial : Talquetamab–Daratumumab in Relapsed or Refractory Myeloma. this is a link to the trial https://www.nejm.org/doi/pdf/10.1056/NEJMoa2604657
Created using ChatSlide
MonumenTAL-3 explores the use of Talquetamab and Daratumumab in treating relapsed/refractory multiple myeloma (RRMM). A critical appraisal by a haematology registrar assesses whether to adopt this treatment in current practice. The clinical need arises from the prevalence of lenalidomide-refractory disease, with GPRC5D×CD3 enhancing T-cell cytotoxicity and Daratumumab potentially boosting immune responses. The trial is a Phase 3, open-label, multicentre randomized controlled trial with a...